Testing a cell therapy for advanced dry AMD with geographic atrophy
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have been diagnosed with dry AMD that has caused a large area of damage (geographic atrophy) in the center of your retina.
- Your vision in the study eye is very poor (20/200 or worse) for Phase 1, or moderately reduced (20/64 or better) for Phase 2a.
- The other (non-study) eye has vision that is at least as good as the study eye.
- You are healthy enough for eye surgery (vitrectomy) and to take medicines that suppress the immune system (immunosuppression).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This trial tests if using your own stem cells to create retinal cells can help treat advanced age-related macular degeneration (AMD). If you have severe vision loss from AMD, this approach may restore some sight.
Hear when a new Retinal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.